Plasma p‐tau217 has been found to differentiate CU from individuals with clinical AD;26 it can detect AD pathology in individuals with MCI;27 and it correlates with Aβ PET, tau PET, and cognitive decline in CU participants.28, 29, 30, 31, 32. Here, MAPT is linked to Alzheimer disease.